•  
  •  
  •  
  •  

2026-08-06 15:56:56

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore

Keywords Selected:  UKMHRA

Stock Report

  • Relonchem Limited receives Marketing Authorization for its two products
  • Relonchem Limited receives Marketing Authorization for two of its products
  • Relonchem Limited receives Marketing Authorization for its products
  • CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
  • Biocon Biologics receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars
  • BrePco Biopharma and Piramal Critical Care announce MHRA approval for Neoatricon® in the UK
  • Relonchem Limited receives Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA
  • Aarti Drugs Ltd's subsidiary receives CGMP certificate from UK MHRA
  • Relonchem Limited receives Marketing Authorization from UKMHRA for its products
  • UK Relonchem Ltd, receives Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets
  • Relonchem Limited receives UKMHRA Marketing Authorization for its products
  • Relonchem Ltd receives Marketing Authorisation for the product Levetiracetam Relonchem 100 mg/mL Oral Solution
  • Sentynl Therapeutics receives marketing authorization for NULIBRY® from the UK MHRA for treatment of MoCD Type A
  • Biocon Biologics Receives MHRA, UK Approval for YESAFILI®, Biosimilar Aflibercept
  • UK MHRA renews GMP compliance of Kopran Ltd's two plants
  • Shilpa Medicare receives UK‐MHRA Approval for Betahistine Dihydrochloride Orodispersible Films, 24 mg
  • Lupin announces Successful Completion of UK MHRA Inspection of its Pithampur Facilities
  • Marksans Pharma Ltd announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution
  • Lupin announces UK MHRA Approval of Lutio® for Treatment of COPD
  • Shilpa Medicare Limited, Unit VI, Bengaluru facility has been issued UK MHRA GMP
  • Brooks Steriscience Ltd recieves UK MHRA marketing authorization for Meropenem Injection
  • Marksans Pharma announces UK MHRA approval for Bells Healthcare All in One Oral Solution
  • Marksans Pharma Limited announces UK MHRA approval for Loperamide 2mg Hard Capsules
  • FDC Limited receives GMP certificate

Latest Post

  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025